In vivo experiments have shown that reducing the expression of BiP in a hypoxic environment leads to the reduction of glucose uptake by tumor cells, thus leading to tumor regression, which may become a potential therapeutic target (52). The gene discussed is HSPA5; the disease is neoplasm.